{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:12:15Z","timestamp":1789963935999,"version":"4.0.1"},"reference-count":48,"publisher":"Impact Journals, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,2,21]]},"DOI":"10.18632\/oncotarget.14588","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T03:26:15Z","timestamp":1484277975000},"page":"12953-12967","source":"Crossref","is-referenced-by-count":50,"title":["Dual SYK\/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment"],"prefix":"10.18632","volume":"8","author":[{"given":"Ailin","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Pathology, Lymphoma Translational Pathology, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Lymphoma Translational Pathology, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Coffey","sequence":"additional","affiliation":[{"name":"Portola Pharmaceuticals, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Conley","sequence":"additional","affiliation":[{"name":"Portola Pharmaceuticals, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Pandey","sequence":"additional","affiliation":[{"name":"Portola Pharmaceuticals, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Lynn","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Lymphoma Translational Pathology, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,1,10]]},"reference":[{"issue":"1","key":"1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Fowler","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Chang","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Jedrzejczak","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Kanan","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Quach","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","article-title":"BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity","volume":"28","author":"Wang","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"7","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2013.131","article-title":"Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy","volume":"27","author":"Wiestner","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"8","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Wiestner","year":"2014","journal-title":"Blood"},{"issue":"4","key":"9","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.18632\/oncotarget.6727","article-title":"Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"16","key":"10","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"O'Brien","year":"2015","journal-title":"Blood"},{"issue":"12","key":"11","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Maddocks","year":"2014","journal-title":"Blood"},{"issue":"24","key":"12","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Wang","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"13","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Lozanski","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Wang","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia","volume":"1","author":"Awan","year":"2015","journal-title":"JAMA Oncol"},{"issue":"13","key":"16","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib","volume":"125","author":"O'Brien","year":"2015","journal-title":"Blood"},{"issue":"14","key":"17","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1182\/blood-2009-10-230060","article-title":"STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells","volume":"115","author":"Estrov","year":"2010","journal-title":"Blood"},{"issue":"7","key":"18","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1073\/pnas.0909086107","article-title":"STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia\/lymphoma cells exposed to oxidative stress","volume":"107","author":"Ozer","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1541-7786.MCR-10-0559","article-title":"STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells","volume":"9","author":"Estrov","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"8","key":"20","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.4049\/jimmunol.1003050","article-title":"CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation","volume":"186","author":"Youinou","year":"2011","journal-title":"J Immunol"},{"issue":"22","key":"21","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2009-09-245811","article-title":"The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment","volume":"116","author":"Wickremasinghe","year":"2010","journal-title":"Blood"},{"issue":"12","key":"22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-011-1218-z","article-title":"Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma","volume":"90","author":"Brockhoff","year":"2011","journal-title":"Ann Hematol"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Lu, Fang, Feng, Jiang, Zhou, Liu, Li, Chen, Ding, Wang, Zhang, Wang. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6 Cancer Lett. 2015; 359(2):250\u2013258.","DOI":"10.1016\/j.canlet.2015.01.021"},{"issue":"3","key":"24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Sinha","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"41","key":"25","doi-asserted-by":"publisher","first-page":"43881","DOI":"10.18632\/oncotarget.6316","article-title":"Cerdulatinib, a novel dual SYK\/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"26","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood.V126.23.3706.3706","article-title":"Predicting cerdulatinib therapeutic concentrations in patients with relapsed\/refractory B cell malignancies using preclinical models and clinical PK\/PD and tumor response correlates","volume":"126","author":"Conley","year":"2015","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Caligaris-Cappio","year":"2009","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Gribben","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2007-04-084756","article-title":"The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"issue":"22","key":"30","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia","volume":"115","author":"Zirlik","year":"2010","journal-title":"Blood"},{"issue":"42","key":"31","doi-asserted-by":"publisher","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"21","key":"32","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1073\/pnas.94.21.11526","article-title":"Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors","volume":"94","author":"Rawlings","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"33","doi-asserted-by":"crossref","first-page":"15595","DOI":"10.1074\/jbc.272.25.15595","article-title":"Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function","volume":"272","author":"Kurosaki","year":"1997","journal-title":"J Biol Chem"},{"issue":"2","key":"34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Yuan","year":"2011","journal-title":"Blood"},{"issue":"9","key":"35","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/leu.2008.163","article-title":"Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2141.2010.08507.x","article-title":"Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals","volume":"153","author":"Michie","year":"2011","journal-title":"Br J Haematol"},{"issue":"24","key":"37","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/blood-2011-02-333773","article-title":"SYK inhibition and response prediction in diffuse large B-cell lymphoma","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"7","key":"38","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration","volume":"26","author":"Burger","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"39","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2013.37","article-title":"Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"27","author":"Friedberg","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"40","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"Sinha","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"41","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Shipp","year":"2010","journal-title":"Blood"},{"issue":"9","key":"42","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"Brown","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"22","key":"43","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Ulrich","year":"2014","journal-title":"Blood"},{"issue":"15","key":"44","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Yasenchak","year":"2015","journal-title":"Blood"},{"key":"45","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","author":"Forconi","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13427","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"170","author":"Wang","year":"2015","journal-title":"Br J Haematol"},{"issue":"23","key":"47","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1182\/blood.V126.23.3929.3929","article-title":"Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK\/JAK Inhibitor in Patients with Relapsed\/Refractory B Cell Malignancies","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"12","key":"48","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Kipps","year":"2008","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T16:37:16Z","timestamp":1589128636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,10]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,2,21]]}},"alternative-id":["14588","28088788"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14588","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,10]]}}}